CETP rs1800548: HDL Levels, I405V, and Health
The rs1800548 variant (often evaluated in literature alongside the I405V missense polymorphism) is a single-nucleotide variant in the cholesteryl ester transfer protein (CETP) gene on chromosome 16. Research associates this variant with variations in high-density lipoprotein cholesterol (HDL-C) concentrations and cardiovascular risk markers. While the variant is tied to altered lipid remodeling, its clinical effects on overall heart disease risk and longevity remain complex and context-dependent.
What each genotype means
Baseline CETP activity
This genotype represents the most common form of the CETP gene in many populations. Research indicates that individuals with this genotype typically exhibit standard levels of cholesteryl ester transfer protein activity, which influences the exchange of lipids between lipoprotein particles. This is considered the reference state against which variations like the I405V change are measured.
This is the most frequent genotype in many global populations, though frequencies vary significantly by ancestry.
Modified lipid transport profile
Carriers of this genotype possess one copy of the variant associated with the I405V change in the CETP protein. Studies suggest this variant is often associated with higher levels of HDL cholesterol, though the clinical impact of these elevated levels on cardiovascular risk remains a subject of ongoing research and debate. You should discuss your overall lipid profile and cardiovascular health with your healthcare provider.
This heterozygous genotype is common, appearing in approximately 30-35% of individuals of European ancestry.
Potential elevated HDL profile
Individuals with this genotype carry two copies of the variant associated with the I405V change. Research has linked this genotype to higher plasma HDL cholesterol levels, as the variant may influence the efficiency of CETP-mediated lipid transfer. While higher HDL is often viewed positively, the relationship between genetically elevated HDL and heart disease risk is complex and not always straightforward; consult your physician to interpret this in the context of your full lipid panel.
This homozygous genotype is less common than the heterozygous form, occurring in a smaller subset of the population depending on ethnic background.
What Is rs1800548 and Where Is It Located?
The single-nucleotide polymorphism rs1800548 sits within the cholesteryl ester transfer protein (CETP) gene located on the long arm of chromosome 16 (16q13). In genomic literature, it is closely cataloged alongside functional variation involving the substitution of an isoleucine for a valine residue at amino acid position 405 (historically labeled as the I405V or Ile405Val variant, annotated via related markers such as rs5882 in exon 14). At this chromosomal position, individuals carry either the ancestral C allele or the alternate T allele. Because CETP is deeply involved in intravascular lipid transport, variants across this locus are frequently genotyped to assess inherited patterns in lipid architecture and circulating cholesterol particles.
The Biological Role of the CETP Gene
The CETP gene encodes cholesteryl ester transfer protein, a plasma glycoprotein synthesized primarily by the liver and adipose tissue before being secreted into circulation. CETP plays a central role in reverse cholesterol transport by facilitating the bidirectional exchange of neutral lipids between lipoproteins. Specifically, it transfers cholesteryl esters from atheroprotective high-density lipoproteins (HDL) to apolipoprotein B-containing lipoproteins, such as very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL), in exchange for triglycerides. Naturally occurring genetic variations that reduce CETP mass or enzymatic activity typically impair this transfer, which subsequently prevents the clearance of cholesteryl esters from HDL and leads to elevated circulating HDL cholesterol concentrations.
Cardiovascular and Cognitive Associations: Strength of Evidence
Epidemiological studies and genome-wide association investigations have consistently observed that genetic variants modulating CETP function, such as the I405V axis, associate with modest elevations in HDL cholesterol levels. However, the downstream clinical consequences of this elevation present a nuanced picture with limited overall evidence for disease reduction. Although higher HDL levels were historically assumed to protect against atherosclerosis, large-scale studies—including investigations in the China Kadoorie Biobank and Mendelian randomization analyses—indicate that genetic elevations in HDL-C through CETP pathways do not automatically translate into lower coronary heart disease risk unless accompanied by reductions in LDL cholesterol. Furthermore, studies exploring CETP variation in relation to cognitive decline, Alzheimer's disease, and exceptional longevity have shown mixed results, demonstrating protective trends in some older cohorts but failing to replicate reliably across diverse ancestry groups.
Population Distribution and Ancestry Differences
The allele frequencies across the CETP I405V locus vary substantially across distinct global populations. Among individuals of European ancestry, the minor allele demonstrates an approximate frequency (MAF) between 30% and 35%. Conversely, in populations of African descent, the alternative valine-encoding variant is observed at significantly higher frequencies, often exceeding 60% and functioning as the predominant ancestral allele. Moderate to high frequencies are also documented in East Asian and South Asian populations. Because the surrounding linkage disequilibrium patterns and lipid baseline profiles differ broadly among ancestries, the statistical correlations between this variant and health endpoints observed in European cohorts cannot be uniformly generalized to other demographic groups.
Interpreting Genetic Data and Clinical Utility
Identifying an rs1800548 genotype provides educational insight into one element of personal lipid biology, but it is not a diagnostic test or an independent predictor of disease. Circulating lipid levels and lifetime cardiovascular vulnerability are multifactorial outcomes governed by hundreds of common genetic variants, dietary intake, physical exercise, and metabolic health. Carriers of variants associated with higher HDL should not interpret their genotype as guaranteed protection against vascular conditions. Routine clinical blood panels that directly measure lipid fractions and non-HDL cholesterol remain the standard for medical risk stratification. Anyone evaluating their cardiovascular disease risk or considering lipid-lowering pharmacological interventions should consult a qualified physician or lipidologist rather than making changes based on direct-to-consumer genetic profiles.
How common is this variant?
The minor allele frequency for rs1800548 and the corresponding I405V alteration ranges between 0.30 and 0.35 in European populations, whereas the alternate allele is significantly more frequent in African populations (often exceeding 0.60).
Frequently asked questions
Does having the rs1800548 variant mean I will have high HDL cholesterol?
Not necessarily. While the variant is statistically linked with modest increases in HDL cholesterol across population studies, genetics is only one factor influencing lipid levels. Diet, exercise, body weight, and other biological traits play significant roles in determining your actual HDL measurements on a blood panel.
Does a higher HDL level from this variant protect against heart disease?
Current scientific evidence indicates that genetically elevated HDL cholesterol does not automatically protect against cardiovascular disease. Large clinical and genetic trials have shown that reducing CETP activity or raising HDL-C in isolation fails to reliably prevent heart attacks unless accompanied by reductions in atherogenic particles such as LDL cholesterol.
Is the CETP I405V variant related to Alzheimer's disease or memory?
Published research on CETP and cognitive decline has produced conflicting findings. Some longitudinal studies observed modest delays in memory loss or lower dementia incidence in certain elderly cohorts, while other rigorous investigations detected no protective effect or reported conflicting directional associations depending on ancestral background.
Can I use my rs1800548 result to adjust my cholesterol medications?
No. Genotype results should never be used to initiate, stop, or adjust prescription medications such as statins or other lipid-modifying therapies. Any modifications to cardiovascular therapies must be guided by standardized blood test results and personalized clinical guidance from your healthcare provider or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1800548?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CETP
CETP promoter variant associated with preserved cognitive function, elevated HDL levels, and exceptional longevity across European cohorts.
The B2 (A) allele of the TaqIB polymorphism is associated with lower CETP activity and significantly higher HDL-cholesterol levels.
The missense variant p.Ile422Val (I405V) in CETP is associated with reduced cholesteryl ester transfer protein activity, leading to elevated HDL-C levels and modest protection against coronary artery disease.
Well-established regulatory intronic polymorphism modulating cholesteryl ester transfer protein activity and circulating HDL cholesterol levels.
Known as the CETP TaqIB polymorphism, this intron variant is linked to reduced CETP activity, higher circulating HDL-C, and altered cardiovascular risk profile.
The I405V coding variant in cholesteryl ester transfer protein correlates with diminished CETP mass, elevated HDL cholesterol levels, and potential longevity benefits.